Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
Saved in:
| Title: | Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. |
|---|---|
| Authors: | Overgaard RV; Department of Quantitative Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark., Lindberg SØ; Department of Medical and Science, Novo Nordisk A/S, Søborg, Denmark., Thielke D; Department of Global Medical Affairs, Novo Nordisk A/S, Søborg, Denmark. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Jan; Vol. 21 (1), pp. 43-51. Date of Electronic Publication: 2018 Aug 23. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.13479 |
